Brains Bioceutical Corp. and major investor DSM Ventureing closed US $ 31.9 million financing
Brains Bioceutical Corp. (“Brains” or “Company”) is pleased to announce the completion of a US $ 31.9 million financing with existing shareholders of DSM Ventureing and Brains. As the primary investor in this cycle, DSM Venture Capital is the corporate venture capital arm of Royal DSM (“DSM”). DSM is a global science-based company active in the fields of health and nutrition. And a sustainable way of life. This historic investment and strategic transaction strengthens Brains’ position as one of the leading cannabinoid (CBD) pharmaceutical companies. Del Morgan & Co. acted as Brains’ financing agent.
“Completion of the financing marks an exciting milestone for the Brains team. Gaining DSM’s confidence in the next round strengthens Brains’ strategic position in the pharmaceutical industry, ”said Rick Brar, CEO and President of Brains. “The demand for isolated CBD active pharmaceutical ingredients (APIs) in the pharmaceutical and healthcare industry continues to grow. Our team has worked tirelessly to position Brains as the market leader in the CBD industry. Our license suite allows Brains to grow rapidly within the industry, ”continued Blair.
Pieter Wolters, Managing Director of DSM Ventureing, commented: “The CBD market is growing rapidly and increasingly strong scientific evidence proves the potential of API CBD in many therapeutic areas. Additionally, consumers are increasingly turning to CBD to solve their health concerns. . Brains’ unrivaled expertise and manufacturing capabilities in the area of CBD, coupled with Godsman’s unique scientific and marketing capabilities in the pharmaceutical arena, make it an ideal partnership to help pharmaceutical companies realize the potential of early drug development. of CBD.
Brains is one of the few companies in the world to produce CBD as an API for pharmaceutical applications, research, development and clinical trials. It is also one of the few commercial manufacturers in Europe to achieve EU-GMDP certification, producing CBD APIs for human and veterinary use in facilities approved by the MHRA. Brains’ API CBD, its leading product on the market, contains 99.7% CBD and zero tetrahydrocannabinol (THC).
Brains’ progress in the development of pure natural CBD benefits scientific and health communities around the world. Brains Phytocannabinoid Pure CBD API has successfully passed the INRS laboratory test of the World Anti-Doping Agency (WADA). These screening reports confirm that Brains API CBD does not contain tetrahydrocannabinol, pesticides and other banned substances listed by WADA. Brains is the first in the industry to obtain such confirmation of the purity of its CBD and the absence of banned substances from a laboratory accredited by WADA. WADA has removed CBD from its list of banned substances. All activities carried out in the UK comply with UK law and are subject to routine and regular inspections by UK authorities.
Brains has also launched its ‘Brains Pure’ branded CBD nutritional supplement in major UK health and wellness retail and pharmacy chains. All Brains products, whether under the Brains brand or the white label, including a collaboration with a leading UK vitamin company, will carry the ‘Brains Inside®’ brand and provide a seal of assurance. quality. Brains is also able to meet the stringent new dietary requirements of the British Food Standards Association (FSA) and the European Food Safety Authority (EFSA) for CBD products in the UK. Brains’ collaboration with DSM Ventureing will allow the company to leverage the strategic partnership that DSM has established since its initial inception in 1902.
About Brain Biopharmaceutical Company.
Brains Bioceutical Corp. is a leader in the production of natural active pharmaceutical ingredients (APIs) in the pharmaceutical and nutraceutical industry which is GMP certified by the European Union. Brains Bioceutical is one of the only manufacturers of natural phytocannabinoid active pharmaceutical ingredients (APIs) currently in commercial production and has participated in global academic and clinical trials. The Brains leadership team is made up of a few pharmaceutical and consumer product executives. They have held managerial and other leadership positions in companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and the Royal Navy. Brains is owned by a wholly British subsidiary. BSPG Laboratories is one of the few companies with commercial capabilities and EU-GMDP certification to produce CBD APIs.
About DSM Entrepreneurship
DSM Ventureing is the corporate venture capital arm of Royal DSM. Royal DSM is a goal-oriented global science company active in nutrition, health and sustainable lifestyles. DSM’s mission is to create a better life for everyone. DSM uses its products and solutions to address some of the world’s greatest challenges, while creating economic, environmental and social value for all stakeholders: customers, employees, shareholders and society as a whole. DSM provides innovative solutions for human nutrition, animal nutrition, personal care and flavors, medical equipment, green products and applications, as well as new mobility and connectivity. DSM and its subsidiaries have approximately 23,000 employees and annual net sales of approximately € 10 billion. The company was founded in 1902 and listed on Euronext Amsterdam.
More information can be found at www.dsm.com/venturing.
This press release contains forward-looking statements or forward-looking information within the meaning of securities laws (“forward-looking statements”). Usually, but not always, forward-looking statements may be made by means of “plans”, “expect” or “unexpected”, “anticipates”, “estimates”, “intentions”, “expects” or “unexpected beliefs” , or variations of such words and expressions, or state that certain actions, events or results “may”, “may”, “shall”, “may” or “shall” occur or be achieved. All statements contained in this press release other than statements of historical fact are forward-looking statements and are based on expectations, estimates and forecasts as of the date of this press release. All statements that involve discussions of predictions, expectations, beliefs, plans, forecasts, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. The risks, uncertainties and other factors involved in forward-looking statements may cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied in such forward-looking statements. Although the company believes that the assumptions and factors used in preparing the forward-looking statements in this press release are reasonable, it cannot guarantee that such statements will prove to be accurate as actual results and future events may differ materially from expectations. In the statement. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The forward-looking statements contained in this press release were made as of the date of this press release. Unless otherwise applicable securities requirements, the Company assumes no obligation to publicly update these forward-looking statements to reflect new information, subsequent events or other circumstances. .